Nutra Pharma Receives Patent for the Use of Cobratoxin as an Analgesic
Nutra Pharma has been issued a patent by the U.S. Patent and Trademark Office for the composition of matter and the use of cobratoxin, a component of cobra venom, for the treatment of pain.
March 11, 2011 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that it has received approval from the United States Patent and Trademark Office (USPTO) for its patent describing the use of cobratoxin as a treatment for chronic pain.
“This patent represents a key addition to our intellectual property portfolio,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As we continue our efforts developing treatments for chronic pain using proteins from cobra venom, this patent will provide important ongoing support and protection of our research and development projects,” he explained.
The patent (US 7,902,152), titled “Use of cobratoxin as an analgesic,” describes a composition of matter for an analgesia and its method of use. The method of use is for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer. The pain associated with neurological conditions, rheumatoid arthritis, viral infections and lesions is also contemplated. The method includes administering to a host an alpha-neurotoxin that is characterized by its ability to block the action of acetylcholine at nicotinic acetylcholine receptors.
Nutra Pharma currently produces three drugs for the treatment of pain: Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe (Stage 2) chronic pain; as well as Nyloxin™ and Nyloxin™ Extra Strength, stronger versions of Cobroxin®. These products are currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress.
"This patent provides protection for the development of Cobratoxin as our top tier analgesic product for the treatment of severe pain," commented Dr. Paul Reid, CEO of ReceptoPharm. "We are continuing in our research and development efforts to provide effective alternatives for the treatment of all levels of chronic and traumatic pain," he concluded.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The issuance of this patent by the USPTO should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.